Pharmacogenetics of antiparkinsonian drug treatment: a systematic review.
Pharmacotherapy is the mainstay in the treatment of Parkinson's disease and the armamentarium of drugs available for the therapy of this disease is still expanding. Anti-Parkinson's disease drugs are effective in reducing the physical symptoms, such as hypokinesia, bradykinesia, rigidity and tremor. However, there is a large interindividual variability in response to anti-Parkinson's disease drugs with respect to both drug efficacy and toxicity. It is thought that genetic variability in genes encoding drug-metabolizing enzymes, drug receptors and proteins involved in pathway signaling is an important factor in determining interindividual variability in drug response. Pharmacogenetics aims at identifying genetic markers associated with drug response. Ideally, knowledge of these genetic markers will enable us to predict an individual's drug response in terms of both efficacy and toxicity. The role of pharmacogenetics in the treatment of Parkinson's disease is relatively unexplored. Therefore, we aim to present a systematic review of the published pharmacogenetic studies in Parkinson's disease and to describe polymorphic genes of interest for future research.
Arbouw
Maurits E L
ME
Utrecht University, Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Faculty of Sciences, Utrecht, The Netherlands.
van Vugt
Jeroen P P
JP
Egberts
Toine C G
TC
Guchelaar
Henk-Jan
HJ
D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D014644:Genetic Variation / Q000235:genetics; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D010597:Pharmacogenetics / Q000379:methods*
D000978:Antiparkinson Agents